U.S. markets close in 2 hours 28 minutes
  • S&P 500

    3,853.99
    -16.30 (-0.42%)
     
  • Dow 30

    31,494.22
    +102.70 (+0.33%)
     
  • Nasdaq

    13,156.32
    -202.47 (-1.52%)
     
  • Russell 2000

    2,243.66
    +12.15 (+0.54%)
     
  • Crude Oil

    61.72
    +1.97 (+3.30%)
     
  • Gold

    1,717.50
    -16.10 (-0.93%)
     
  • Silver

    26.40
    -0.48 (-1.80%)
     
  • EUR/USD

    1.2080
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • GBP/USD

    1.3979
    +0.0022 (+0.16%)
     
  • USD/JPY

    106.9340
    +0.2240 (+0.21%)
     
  • BTC-USD

    51,430.80
    +3,614.27 (+7.56%)
     
  • CMC Crypto 200

    1,029.69
    +41.59 (+4.21%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

  • Oops!
    Something went wrong.
    Please try again later.
Portnoy Law
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The investigation focuses on whether Sarepta issued misleading and/or false statements and/or failed to disclose information pertinent to investors. On January 7, 2021, it was announced by Sarepta that its one-time gene therapy for Duchenne muscular dystrophy had failed to show patient benefits in comparison to a placebo. On January 8, 2021, shares of Sarepta suffered a massive drop, based on this news.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising